BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
Key Highlights
- ➤BP-80 well tolerated in primates, with a 50 mg/kg/dose NOEL.
- ➤TILsRx-001 showed 49-fold higher PD-L1 binding affinity after two CD80 mutations.
- ➤Engineered CD80-Fc variant delivered more than 130-fold stronger PD-L1 binding.
- ➤Bria-OTS+ sustained cancer-cell killing across multiple tumor models.
- ➤William V. Williams said findings support continued immunotherapy pipeline development.
Expert Statements
William V. Williams, President and CEO of BriaCell Therapeutics Corp.
“These findings provide additional preclinical support for our cellular immunotherapy and checkpoint inhibitor programs, including Bria-BRES+ in breast cancer and Bria-PROS+ in prostate cancer.”
William V. Williams, President and CEO of BriaCell Therapeutics Corp.
“The results support continued development of our immunotherapy pipeline across multiple cancer indications.”
* Bria-OTS+™ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor models * BriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition PHILADELPHIA and VANCOUVER, British Columbia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced preclinical findings from four posters at the Society for Immunotherapy of Cancer (SITC) 41(th) Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.
The presentations highlight BriaCell’s Bria-OTS+ off-the-shelf cellular immunotherapy platform and BriaPro’s BP-80 and TILsRx immunotherapy programs, including advances in engineered CD80 proteins.
Get started
Create a free account to read the full story.